--- description: An expected deal of $100 billion would add to a feverish year among health care industry deals, racking up a worldwide total of $1 trillion title: Pfizer Bid on AstraZeneca Moves Closer image: https://static.time.com/v3/assets/bltea6093859af6183b/bltde43ab1b5aa15bc0/69868cc5810bbb81dcc9145e/98287005.jpg?branch=production&width=3840&quality=75&auto=webp&crop=16:9 ---  * [World](/section/world/) ## World Update your preferences in [Account Settings](/account/preferences/) Close * [Companies](/tag/companies/) ## Companies Update your preferences in [Account Settings](/account/preferences/) Close # Pfizer's $100 Billion Bid for AstraZeneca 'Imminent' by [Per Liljas](/author/per-liljas/) ## Per Liljas Update your preferences in [Account Settings](/account/preferences/) Close Apr 28, 2014 9:03 AM CUT  Cholesterol drugs, Crestor, left, manufactured by AstraZeneca Plc, and Lipitor, manufactured by Pfizer Inc., are arranged for a photrograph at New London Pharmacy in New York, U.S., on Tuesday, April 6, 2010. Cholesterol drugs, Crestor, left, manufactured by AstraZeneca Plc, and Lipitor, manufactured by Pfizer Inc., are arranged for a photrograph at New London Pharmacy in New York, U.S., on Tuesday, April 6, 2010.JB Reed—Bloomberg / Getty Images by [Per Liljas](/author/per-liljas/) ## Per Liljas Update your preferences in [Account Settings](/account/preferences/) Close Apr 28, 2014 9:03 AM CUT Pfizer is reportedly [readying](http://online.wsj.com/news/articles/SB10001424052702304163604579528520220949680?mg=reno64-wsj&url=http%3A%2F%2Fonline.wsj.com%2Farticle%2FSB10001424052702304163604579528520220949680.html "undefined") a bid for pharmaceutical rival AstraZeneca in a deal that would create a $300 billion behemoth offering drugs for most major health conditions, including diabetes, heart disease and rheumatoid arthritis. The last year has seen a flurry of action in the health care industry, with a total deal volume of $1 trillion worldwide. The _Financial Times_ has previously reported on Pfizer’s interest in U.K. firm AstraZeneca, and now the _Wall Street_ _Journal_ quotes people familiar with the matter as saying an offer of around $100 billion is “imminent.” One of the most tempting prospects of the tie-up would be to combine Pfizer’s targeted cancer therapies with AstraZeneca’s immunotherapies, which are broadly viewed as the next wave of lucrative cancer treatments. The deal would follow Valeant Pharmaceuticals International’s offer last week to buy Allergan Inc. for almost $46 billion, and Novartis AG’s deals to sell and exchange businesses with GlaxoSmithKline PLC and Eli Lilly & Co. in deals worth more than $20 billion. \[[_WSJ_](http://online.wsj.com/news/articles/SB10001424052702304163604579528520220949680?mg=reno64-wsj&url=http%3A%2F%2Fonline.wsj.com%2Farticle%2FSB10001424052702304163604579528520220949680.html "undefined")\] ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/78943/pfizer-astrazeneca-pharmaceutical-bid-deal/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/78943/pfizer-astrazeneca-pharmaceutical-bid-deal/"},"headline":"Pfizer's $100 Billion Bid for AstraZeneca 'Imminent'","datePublished":"2014-04-28T09:03:53.000Z","dateModified":"2026-02-21T07:31:42.997Z","description":"An expected deal worth $100 billion would add to an already feverish year for health care industry deals, racking up a worldwide total of $1 trillion. The union would also combine two promising strands of cancer drugs","url":"https://time.com/78943/pfizer-astrazeneca-pharmaceutical-bid-deal/","keywords":["Companies","big pharma","deal"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/bltde43ab1b5aa15bc0/69868cc5810bbb81dcc9145e/98287005.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Per Liljas","jobTitle":null,"url":"https://time.com/author/per-liljas/"}],"articleSection":"World","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/bltde43ab1b5aa15bc0/69868cc5810bbb81dcc9145e/98287005.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"98287005","caption":"Cholesterol drugs, Crestor, left, manufactured by AstraZeneca Plc, and Lipitor, manufactured by Pfizer Inc., are arranged for a photrograph at New London Pharmacy in New York, U.S., on Tuesday, April 6, 2010.","creditText":"JB Reed—Bloomberg / Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/world/","name":"World"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/companies/","name":"Companies"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/78943/pfizer-astrazeneca-pharmaceutical-bid-deal/","name":"Pfizer's $100 Billion Bid for AstraZeneca 'Imminent'"}}]}] ```